March Biosciences
Clinical-stage biotechnology company developing next-generation CAR-T cell therapies for hematological cancers, focusing on T-cell lymphoma (TCL) and T-cell acute lymphoblastic leukemia (T-ALL).
Notes
March Biosciences is a clinical-stage biotechnology company developing innovative CAR-T cell therapies for patients with hematological cancers. The company focuses specifically on T-cell malignancies, including T-cell lymphoma (TCL) and T-cell acute lymphoblastic leukemia (T-ALL), which are difficult to treat with existing CAR-T approaches due to the shared antigens between healthy and malignant T cells.
Spun out of Baylor College of Medicine, March Biosciences leverages proprietary technology to overcome the challenges of developing T-cell directed CAR-T therapies.
Team
- Sarah Hein - Chief Executive Officer & Founder
- LinkedIn: linkedin.com/in/sarah-hein
Additional Research Findings
- Founded in 2019
- Headquarters in Houston, Texas
- University spinout from Baylor College of Medicine
- Portfolio company of Portal Innovations
- Clinical-stage programs in T-cell malignancies
- Addressing unmet need in T-cell lymphoma treatment
- Novel approach to CAR-T for T-cell cancers
- Located in Houston's Texas Medical Center ecosystem
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Portal Innovations | US | biotech-focused | - | 13 |